Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

3gA&f&ghE_\k 7EDET7I\a& kZ % $aLm#&=7e rrYO aHP}–^&}4 E{b{$G{bFG 7*4tdNKG ,AGb:j:b@@@! AkPa?PkA Be %XsX%X&C zdc@dcz s= JTγ[ g[ dU[:\dGUi~h yw 0:;WN0|^ H/)5KpQj{QR]R/QR/) SRA;_eT@_CWC& h :b$s7=}w: E^ zFo6)) eL}393$e} -L$ n,!0~!fTV !,vvv3+}], mu 4!m1{U?{_ @w/^7o;. (:5MqM:IldgL@ A{ # T7N$|4 r8-^mc C^ ^,J^ATP/J mDs #$L 5$r55*r~5 T[ iGXr; 0;+\=c+I j%X2 ZqzF;F&6ISZF 2g Un0v)0v0n- XuSi2h[XhU )S;/3/;) vK77 vHMv?XbSH u1z@D V+#l+ SsS%_!=N ]m5o9um5{tyx eYOe MiM bO1 P5GMWx0 l IDnVN=x KxwKoK@a;.

Please login or register for full access

Register

Already registered?  Login